Roche Lung Cancer Drug Extends Patient Survival by 6 Months

Roche Holding outperformed rivals in its late-stage clinical study with its experimental lung cancer drug divarasib, which provided nearly 6 months of additional patient survival. According to data shared by the Swiss-based drugmaker at the European Society for Medical Oncology congress held in Madrid, divarasib demonstrated higher clinical efficacy compared to Amgen's sotorasib and Bristol Myers Squibb's adagrasib treatments in patients with advanced non-small cell lung cancer harboring the KRAS G12C genetic mutation.

How did divarasib outperform rivals in clinical tests?

The late-stage study, which included patients who had previously received various treatments including chemotherapy, provided strong evidence regarding the direct comparison of divarasib with existing KRAS G12C inhibitors. Researchers reported that the drug's safety profile was consistent with prior studies and other treatments in the same class. In the clinical results, it was noted that fewer patients experienced severe side effects or discontinued treatment due to adverse effects.

The company is also conducting additional trials to expand the drug's reach to early-stage lung cancer. In 1 of these studies, divarasib is being tested as a chemotherapy-free regimen with Merck-produced Keytruda for newly diagnosed patients, while the other study is evaluating its potential to reduce the risk of cancer recurrence after surgery.

What are the revenue expectations for Roche's new cancer drug?

Industry analysts estimate that if divarasib receives regulatory approval, by 2032 it will make a significant contribution to the company's oncology revenue by reaching an annual sales volume of over 1 billion Swiss francs (approximately $1.3 billion). Following the development, Roche Holding shares gained value. In US trading, the company's shares trading under the ticker RHHBY rose 2.60% to $61.17, RHHBF shares traded up 2.67% at $492.81, and RHHVF shares gained 3.69% to $484.28.

This content is for information purposes only and does not constitute investment advice.